Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Aclaris Therapeutics Inc's Business Segments
Aclaris Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 2 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Dermatology Therapeutics Segment73.1%
- License and Service73.1%
- Contract Research Segment26.9%
- Laboratory Research Revenue26.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Dermatology Therapeutics Segment | $ 1 | 73.1% |
| License and Service | $ 1 | 73.1% |
| Contract Research Segment | $ 1 | 26.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Aclaris Therapeutics Inc dataset.
Description of Aclaris Therapeutics Inc
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address the unmet needs in medical and aesthetic dermatology. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics is dedicated to improving the lives of patients suffering from skin conditions and is committed to discovering novel therapies that can provide meaningful benefits. The company has a strong pipeline of drug candidates targeting various dermatological indications such as common warts, alopecia, vitiligo, and seborrheic keratosis, among others.
The company's key focus area is the development of JAK inhibitors, a class of drugs that target the Janus kinase family of enzymes. JAK inhibitors have demonstrated potential in treating various dermatological disorders by inhibiting the signaling pathways involved in the pathogenesis of these conditions.
Aclaris Therapeutics' lead product candidate is ATI-502, an investigational topical JAK inhibitor, being developed for the treatment of alopecia areata, an autoimmune disease that results in hair loss. The company has completed Phase 2 and Phase 3 clinical trials for ATI-502 and is currently awaiting regulatory approval.
In addition to ATI-502, Aclaris Therapeutics has a robust pipeline of other drug candidates in various stages of development. Some notable candidates include ATI-450 for seborrheic keratosis, ATI-1777 for moderate-to-severe atopic dermatitis, and ATI-2138 for vitiligo.
Apart from its drug development activities, Aclaris Therapeutics also focuses on the commercialization of its approved products. The company has strategic partnerships and agreements with pharmaceutical companies for the distribution and marketing of its drugs in various global markets.
In terms of research and development, Aclaris Therapeutics maintains a strong scientific team comprising of experts in dermatology, immunology, and drug discovery. The company actively invests in research collaborations and partnerships to leverage external expertise and stay at the forefront of dermatological innovation.
Aclaris Therapeutics places a strong emphasis on patient-centricity and aims to address the unmet medical and aesthetic needs of individuals with various skin conditions. The company's vision is to make a meaningful impact on dermatologic healthcare by providing safe and effective therapies that can transform the lives of millions of patients worldwide.
Aclaris Therapeutics is dedicated to improving the lives of patients suffering from skin conditions and is committed to discovering novel therapies that can provide meaningful benefits. The company has a strong pipeline of drug candidates targeting various dermatological indications such as common warts, alopecia, vitiligo, and seborrheic keratosis, among others.
The company's key focus area is the development of JAK inhibitors, a class of drugs that target the Janus kinase family of enzymes. JAK inhibitors have demonstrated potential in treating various dermatological disorders by inhibiting the signaling pathways involved in the pathogenesis of these conditions.
Aclaris Therapeutics' lead product candidate is ATI-502, an investigational topical JAK inhibitor, being developed for the treatment of alopecia areata, an autoimmune disease that results in hair loss. The company has completed Phase 2 and Phase 3 clinical trials for ATI-502 and is currently awaiting regulatory approval.
In addition to ATI-502, Aclaris Therapeutics has a robust pipeline of other drug candidates in various stages of development. Some notable candidates include ATI-450 for seborrheic keratosis, ATI-1777 for moderate-to-severe atopic dermatitis, and ATI-2138 for vitiligo.
Apart from its drug development activities, Aclaris Therapeutics also focuses on the commercialization of its approved products. The company has strategic partnerships and agreements with pharmaceutical companies for the distribution and marketing of its drugs in various global markets.
In terms of research and development, Aclaris Therapeutics maintains a strong scientific team comprising of experts in dermatology, immunology, and drug discovery. The company actively invests in research collaborations and partnerships to leverage external expertise and stay at the forefront of dermatological innovation.
Aclaris Therapeutics places a strong emphasis on patient-centricity and aims to address the unmet medical and aesthetic needs of individuals with various skin conditions. The company's vision is to make a meaningful impact on dermatologic healthcare by providing safe and effective therapies that can transform the lives of millions of patients worldwide.
Aclaris Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for dermatological and immunological diseases. The company aims to address unmet medical needs through its product pipeline, which includes both approved products and those in various stages of clinical development. Here, I will describe the segments, products, and services offered by Aclaris Therapeutics in detail.
Segments
Aclaris operates primarily in the following segments:
1. Dermatology:
- This segment focuses on conditions that affect the skin, hair, and nails. The company aims to provide effective treatments for common yet impactful dermatological disorders.
2. Immunology:
- Aclaris also explores treatment options for various immunological conditions, specifically those that can exacerbate dermatological issues.
Products
Aclaris Therapeutics has developed a range of products that are either marketed or in various stages of clinical trials. These products can be categorized into approved therapies and investigational candidates.
1. Approved Products:
- Kybella: An injectable treatment for reducing moderate to severe fat below the chin, although Aclaris does have similar product candidates aimed at addressing fat in specific areas.
- Aldara (Imiquimod): A topical cream that aids in treating superficial basal cell carcinoma, genital warts, and actinic keratosis.
2. Investigational Products:
- ATI-1777: This is an investigational topical therapy designed for inflammatory skin conditions. Its target indications include atopic dermatitis and other inflammatory diseases.
- ATI-2139: An oral therapy targeting the treatment of alopecia areata, which has shown promise in clinical trials.
3. Combination Products:
- Aclaris explores the effectiveness of combining different therapeutic agents to enhance outcomes for patients with certain dermatological conditions.
Services
In addition to its product offerings, Aclaris Therapeutics provides various services that may include:
1. Clinical Development:
- Aclaris conducts extensive clinical trials to test the safety and efficacy of its investigational therapies. The company has protocols in place to evaluate patient outcomes and gather data critical to regulatory submissions.
2. Compassionate Use Programs:
- For patients with no alternative treatment options, Aclaris may offer compassionate use programs that allow access to investigational drugs outside of clinical trials.
3. Patient Support Programs:
- Aclaris may provide resources and support for patients using their approved therapies, including educational materials, access to healthcare professionals, and adherence programs.
4. Collaboration and Licensing:
- Aclaris often collaborates with other biopharmaceutical and academic institutions to enhance its research efforts and explore new therapeutic avenues. Licensing agreements may also be in place to distribute or co-develop treatments.
Research & Development Focus
Aclaris’s R&D efforts emphasize on understanding the mechanisms behind dermatological and immunological diseases. The company invests in developing novel therapies that target underlying biological pathways, with an aim to provide improved treatment options for patients.
Conclusion
Aclaris Therapeutics, Inc. is dedicated to innovation in the dermatology and immunology space, continuously working to expand its product pipeline and enhance patient care through various services. The company’s commitment to addressing unmet medical needs drives its research and development activities, as it seeks to bring effective therapies to market that can significantly improve the quality of life for patients with dermatological and immunological conditions.
Segments
Aclaris operates primarily in the following segments:
1. Dermatology:
- This segment focuses on conditions that affect the skin, hair, and nails. The company aims to provide effective treatments for common yet impactful dermatological disorders.
2. Immunology:
- Aclaris also explores treatment options for various immunological conditions, specifically those that can exacerbate dermatological issues.
Products
Aclaris Therapeutics has developed a range of products that are either marketed or in various stages of clinical trials. These products can be categorized into approved therapies and investigational candidates.
1. Approved Products:
- Kybella: An injectable treatment for reducing moderate to severe fat below the chin, although Aclaris does have similar product candidates aimed at addressing fat in specific areas.
- Aldara (Imiquimod): A topical cream that aids in treating superficial basal cell carcinoma, genital warts, and actinic keratosis.
2. Investigational Products:
- ATI-1777: This is an investigational topical therapy designed for inflammatory skin conditions. Its target indications include atopic dermatitis and other inflammatory diseases.
- ATI-2139: An oral therapy targeting the treatment of alopecia areata, which has shown promise in clinical trials.
3. Combination Products:
- Aclaris explores the effectiveness of combining different therapeutic agents to enhance outcomes for patients with certain dermatological conditions.
Services
In addition to its product offerings, Aclaris Therapeutics provides various services that may include:
1. Clinical Development:
- Aclaris conducts extensive clinical trials to test the safety and efficacy of its investigational therapies. The company has protocols in place to evaluate patient outcomes and gather data critical to regulatory submissions.
2. Compassionate Use Programs:
- For patients with no alternative treatment options, Aclaris may offer compassionate use programs that allow access to investigational drugs outside of clinical trials.
3. Patient Support Programs:
- Aclaris may provide resources and support for patients using their approved therapies, including educational materials, access to healthcare professionals, and adherence programs.
4. Collaboration and Licensing:
- Aclaris often collaborates with other biopharmaceutical and academic institutions to enhance its research efforts and explore new therapeutic avenues. Licensing agreements may also be in place to distribute or co-develop treatments.
Research & Development Focus
Aclaris’s R&D efforts emphasize on understanding the mechanisms behind dermatological and immunological diseases. The company invests in developing novel therapies that target underlying biological pathways, with an aim to provide improved treatment options for patients.
Conclusion
Aclaris Therapeutics, Inc. is dedicated to innovation in the dermatology and immunology space, continuously working to expand its product pipeline and enhance patient care through various services. The company’s commitment to addressing unmet medical needs drives its research and development activities, as it seeks to bring effective therapies to market that can significantly improve the quality of life for patients with dermatological and immunological conditions.